Literature DB >> 2857946

Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro.

D D Ho, K L Hartshorn, T R Rota, C A Andrews, J C Kaplan, R T Schooley, M S Hirsch.   

Abstract

Recombinant human interferon alfa-A (rIFN alpha A) had a dose-related suppressive effect on human T lymphotropic virus type III (HTLV-III) replication in vitro in normal peripheral-blood mononuclear cells (PBMC). Both single-dose and multiple-dose regimens were inhibitory. Such inhibitory concentrations (4-1024 units/ml) were not toxic to PBMC in culture, and were within the ranges achievable in blood after injection. These studies suggest that clinical trials of rIFN alpha A in early HTLV-III infection are warranted.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2857946     DOI： 10.1016/s0140-6736(85)92144-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  80 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 2.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

Authors:  David M Asmuth; Robert L Murphy; Susan L Rosenkranz; Juan J L Lertora; Shyam Kottilil; Yoninah Cramer; Ellen S Chan; Robert T Schooley; Charles R Rinaldo; Nathan Thielman; Xiao-Dong Li; Sharon M Wahl; Jessica Shore; Jennifer Janik; Richard A Lempicki; Yaa Simpson; Richard B Pollard
Journal:  J Infect Dis       Date:  2010-06-01       Impact factor: 5.226

Review 4.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

5.  The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.

Authors:  E Priel; S D Showalter; M Roberts; S Oroszlan; D G Blair
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

Review 6.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

7.  Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol.

Authors:  T S Lin; R Schinazi; B P Griffith; E M August; B F Eriksson; D K Zheng; L A Huang; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

8.  Recombinant human gamma interferon enhances in vitro activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome.

Authors:  W Heagy; T B Strom; V E Kelley; J Collela; C Crumpacker; J M Williams; H M Shapiro; L Laubenstein; R Finberg
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

9.  Maternal transmission of retroviral disease and strategies for preventing infection of the neonate.

Authors:  A H Sharpe; J J Hunter; R M Ruprecht; R Jaenisch
Journal:  J Virol       Date:  1989-03       Impact factor: 5.103

10.  Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses.

Authors:  Julia Bitzegeio; Marissa Sampias; Paul D Bieniasz; Theodora Hatziioannou
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.